Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases
Executive Summary
Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he is hopeful a national settlement framework will be finalized.